User: Guest  Login
Title:

Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.

Document type:
journal article
Author(s):
Stuve, O, O; Hartung, H P, HP; Freedman, M, M; Li, D, D; Hemmer, B, B; Kappos, L, L; Rieckmann, P, P; Montalban, X, X; Ziemssen, T, T; Selmaj, K, K
Abstract:
In the adaptive dose-ranging, 6- or 3-month BOLD study in patients with relapsing-remitting multiple sclerosis, once-daily siponimod (BAF312) showed dose-dependent reduction of combined unique active lesion number and annualized relapse rate (ARR); near-maximal effects were observed at 2mg. Here, we report the efficacy findings of first 12 months of the extension (representing>18 or 15 months of total treatment).Patients either continued on siponimod doses assigned in the core phase or were re-...     »
Journal title abbreviation:
Mult Scler Relat Disord
Year:
2014
Journal volume:
3
Journal issue:
6
Pages contribution:
754-5
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/25891595
Print-ISSN:
2211-0348
TUM Institution:
Neurologische Klinik und Poliklinik
 BibTeX